Naloxonazine, a specific mu-opioid receptor antagonist, attenuates the increment of locomotor activity induced by acute methamphetamine in mice

Toxicology Letters

Volumn 212, Issue 1, 2012, Pages 61-65

  Chien, Chih Cheng ^a,b   Lee, Yih Jing ^b   Fan, Lir Wan ^c   Ho, Ing Kang ^d,e   Tien, Lu Tai ^b  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Dopaminergic transmission; Locomotor activity; Methamphetamine; Naloxonazine; Striatum

Indexed keywords

METHAMPHETAMINE; NALOXONAZINE; PHOSPHOPROTEIN DARPP 32; SODIUM CHLORIDE; THREONINE;

ANIMAL EXPERIMENT; ARTICLE; ATTENUATION; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INJECTION VOLUME; GROWTH INHIBITION; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE;

ANIMALS; BLOTTING, WESTERN; CORPUS STRIATUM; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DRUG INTERACTIONS; MALE; METHAMPHETAMINE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; PHOSPHORYLATION; RECEPTORS, OPIOID, MU; VIDEO RECORDING;

MUS;

EID: 84861434520     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.04.022     Document Type: Article

References (35)

1. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nature Neuroscience 2008, 11:932-939.
2. Bibb J.A., Snyder G.L., Nishi A., Yan Z., Meijer L., Fienberg A.A., Tsai L.H., Kwon Y.T., Girault J.A., Czernik A.J., Huganir R.L., Hemmings H.C., Nairn A.C., Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 1999, 402:669-671.
3. Borgkvist A., Marcellino D., Fuxe K., Greengard P., Fisone G. Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. Neuropharmacology 2008, 54:31-35.
4. Chen P.C., Chen J.C. Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats. Neuropsychopharmacology 2005, 30:538-549.
5. Chiu C.T., Ma T., Ho I.K. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Research Bulletin 2005, 67:100-109.
6. de Gortari P., Mengod G. Dopamine D1, D2 and mu-opioid receptors are co-expressed with adenylyl cyclase 5 and phosphodiesterase 7B mRNAs in striatal rat cells. Brain Research 2010, 1310:37-45.
7. Dourmap N., Michael-Titus A., Costentin J. Differential effect of intrastriatal kainic acid on the modulation of dopamine release by mu- and delta-opioid peptides: a microdialysis study. Journal of Neurochemistry 1992, 58:709-713.
8. Dourmap N., Clero E., Costentin J. Involvement of cholinergic neurons in the release of dopamine elicited by stimulation of mu-opioid receptors in striatum. Brain Research 1997, 749:295-300.
9. Durieux P.F., Schiffmann S.N., de Kerchove d'Exaerde A. Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions. The EMBO Journal 2012, 31:640-653.
10. Frankel P.S., Hoonakker A.J., Danaceau J.P., Hanson G.R. Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine. Pharmacology Biochemistry and Behavior 2007, 86:511-515.
11. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
12. Greengard P., Allen P.B., Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
13. Itzhak Y., Ali S.F. Behavioral consequences of methamphetamine-induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction. Annals of the New York Academy of Sciences 2002, 965:127-135.
14. Jang C.G., Lee S.Y., Loh H.H., Ho I.K. Lack of mu-opioid receptor leads to an increase in the NMDA receptor subunit mRNA expression and NMDA-induced convulsion. Brain Research Molecular Brain Research 2001, 94:105-111.
15. Ku T.H., Lee Y.J., Wang S.J., Fan C.H., Tien L.T. Effect of honokiol on activity of GAD(65) and GAD(67) in the cortex and hippocampus of mice. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2011, 18:1126-1129.
16. Kubota Y., Inagaki S., Kito S., Takagi H., Smith A.D. Ultrastructural evidence of dopaminergic input to enkephalinergic neurons in rat neostriatum. Brain Research 1986, 367:374-378.
17. Kuczenski R., Segal D.S., Aizenstein M.L. Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. Journal of Neuroscience 1991, 11:2703-2712.
18. Lan K.C., Ma T., Lin-Shiau S.Y., Liu S.H., Ho I.K. Methamphetamine-elicited alterations of dopamine- and serotonin-metabolite levels within mu-opioid receptor knockout mice: a microdialysis study. Journal of Biomedical Science 2008, 15:391-403.
19. Mocchetti I., Naranjo J.R., Costa E. Regulation of striatal enkephalin turnover in rats receiving antagonists of specific dopamine receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 1987, 241:1120-1124.
20. Mori T., Ito S., Narita M., Suzuki T., Sawaguchi T. Combined effects of psychostimulants and morphine on locomotor activity in mice. Journal of Pharmacological Sciences 2004, 96:450-458.
21. Nakano T., Doi T., Yoshimoto J., Doya K. A kinetic model of dopamine- and calcium-dependent striatal synaptic plasticity. PLoS Computational Biology 2010, 6:e1000670.
22. Nestler E.J., Alreja M., Aghajanian G.K. Molecular control of locus coeruleus neurotransmission. Biological Psychiatry 1999, 46:1131-1139.
23. Nishi A., Bibb J.A., Snyder G.L., Higashi H., Nairn A.C., Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:12840-12845.
24. Nishi A., Bibb J.A., Matsuyama S., Hamada M., Higashi H., Nairn A.C., Greengard P. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. Journal of Neurochemistry 2002, 81:832-841.
25. Park Y., Jang C.G., Yang K.H., Loh H.H., Ma T., Ho I.K. Regional specific increases of [3H]AMPA binding and mRNA expression of AMPA receptors in the brain of mu-opioid receptor knockout mice. Brain Research Molecular Brain Research 2003, 113:116-123.
26. Scheggi S., Crociani A., De Montis M.G., Tagliamonte A., Gambarana C. Dopamine D1 receptor-dependent modifications in the dopamine and cAMP-regulated phosphoprotein of Mr 32kDa phosphorylation pattern in striatal areas of morphine-sensitized rats. Neuroscience 2009, 163:627-639.
27. Shen X., Purser C., Tien L.T., Chiu C.T., Paul I.A., Baker R., Loh H.H., Ho I.K., Ma T. mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. Journal of Neuroscience Research 2010, 88:2294-2302.
28. Stoof J.C., Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981, 294:366-368.
29. Svenningsson P., Fienberg A.A., Allen P.B., Moine C.L., Lindskog M., Fisone G., Greengard P., Fredholm B.B. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP-32. Journal of Neurochemistry 2000, 75:248-257.
30. Tang A.H., Franklin S.R. Acquisition of brightness discrimination in the rat is impaired by opiates with psychotomimetic properties. Pharmacology Biochemistry and Behavior 1983, 18:873-877.
31. Tien L.T., Ho I.K. Involvement of mu-opioid receptor in methamphetamine-induced behavioral sensitization. Current Neuropharmacology 2011, 9:215-218.
32. Ujike H., Onoue T., Akiyama K., Hamamura T., Otsuki S. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 1989, 98:89-92.
33. Vonk A., Reinart R., Rinken A. Modulation of adenylyl cyclase activity in rat striatal homogenate by dopaminergic receptors. Journal of Pharmacological Sciences 2008, 108:63-70.
34. White F.J., Cooper D.C. The vicious cyclin of addiction. Nature Medicine 2001, 7:416-417.
35. Zachariou V., Sgambato-Faure V., Sasaki T., Svenningsson P., Berton O., Fienberg A.A., Nairn A.C., Greengard P., Nestler E.J. Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action. Neuropsychopharmacology 2006, 31:555-562.